Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024Metronidazole for bacterial infection
February 1, 2023